Dr. iur. Julia Schieber
Biography
Julia is a partner in Baker McKenzie's life sciences and IP and Technology team. She is experienced in IP transactions with a particular focus on the healthcare industry. Prior to joining Baker McKenzie, Julia worked for major law firms in Munich and New York City. In 2018, she was seconded to Novartis.
Julia has been ranked as a Next Generation Lawyer for life sciences in Switzerland by The Legal 500, and for IP by Managing IP. Clients appreciate Julia for "her 'profound' industry knowledge" (The Legal 500).
Practice Focus
Julia advises a broad range of clients in the life sciences and technology industries, from start-ups, venture capital investors, biotechnology, medical device, diagnostic companies to global pharmaceutical companies on a wide range of licensing, collaborations, joint ventures, strategic alliances, and other intellectual property-focused transactions. She assists life sciences and technology companies with commercial transactions related to manufacturing, supply, distribution, and commercialization of technology and products. Julia also represents research and academic institutions in forming public-private partnerships and drafting and negotiating various agreements such as consortium, grant, joint research, and sponsored research. She also advises clients in connection with investments, fundraisings and M&A.
Representative Legal Matters
- Advised Numab Therapeutics on its USD 1.25 billion sale of its atopic dermatitis spin-off to Johnson & Johnson
- Advised CureVac on its licensing deal with GSK for mRNA candidate vaccines for influenza and COVID-19 globally in consideration for EUR 400 million upfront and up to an additional EUR 1.05 billion in milestones as well as tiered royalties
- Advised Galapagos on the intended transfer of its Jyseleca® business to Alfasigma, including the European and UK Marketing Authorizations, the commercial, medical and development activities for Jyseleca® and approximately 400 FTEs in 14 European countries..
- Advised Sino Biopharmaceutical on its partnership with Boehringer Ingelheim to bring innovative cancer therapies to China.
- Advised a global pharmaceutical company on a number of licensing and collaboration agreements.
- Advised GSK on its license agreement with WuXi Biologics for multiple novel bi- and multi-specific T cell engagers.
- Advised CureTeq on its licensing agreement with Merck for oncology asset M8891.
- Advised CureVac on its collaboration agreement with myNeo N.V. for identifying novel antigen targets for mRNA-based cancer vaccine development.
- Advised the founders of Digital Republic on selling the company to mobilezone Group.
- Advised Adagene on its collaboration with Sanofi for novel masked immuno-oncology antibody candidates.
Professional Honors
- Next Generation Lawyer for Life Sciences, The Legal 500, 2023-2024
- Rising Star Switzerland for Life Sciences, The Legal 500, 2021-2022
- Rising Star Switzerland for Intellectual Property, Managing IP, 2022
- Award of the Foundation for Science and Society at the University of Konstanz
- Stiftung Wissenschaft und Gesellschaft for the best PhD thesis, 2012-2013
Professional Associations and Memberships
- Member, Licensing Executives Society
- Member, Institute for Intellectual Property Rights in Switzerland
- Member, German Association for the Protection of Intellectual Property & Copyright
Admissions
- Germany (2015)
- Switzerland (2015)
Education
- High Regional Court of Stuttgart (Second State Exam) (2014)
- University of Konstanz (Dr. jur.) (2012)
- University of California at Los Angeles (Legal Research) (2011)
- University of Konstanz (First State Exam) (2009)
- University of Montpellier (Exchange Student) (2007)
- University of Santo Tomas (Exchange Student) (2007)
Languages
- English
- French
- German
- Spanish
Baker McKenzie Switzerland AG is a member of Baker & McKenzie International, a Swiss Verein.